Zidovudine (▾ Retrovir - Wellcome) is active against the human immunodeficiency virus (HIV). It is the first drug licensed for ‘the management of the serious manifestations of HIV infection in patients with Acquired Immunodeficiency Syndrome (AIDS) or AIDS-related complex (ARC)’. This article discusses clinical experience with zidovudine so far, and how it may be best used.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.